Please assess the completion status of the following clinical trial:

Trial Title: Effect of Food on the Pharmacokinetics of Apremilast (CC-10004) in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy male or female subjects of any ethnic origin between ages of 18 and 65 inclusive with a body mass index (BMI) between 18 and 33.~2. Females who are able to become pregnant have a negative pregnancy test at screening and baseline, and must agree to use one of the following:~   * a highly effective form of contraception (ex. Non-oral hormonal, intrauterine device) OR~  * oral hormonal contraceptive plus one additional form of barrier contraception OR~  * Two forms of barrier contraception These must be effective by the time of screening.~3. All other females must have been surgically sterilized at least 6 months prior to screening or be postmenopausal (to be confirmed by lab tests).~4. Males must agree to use latex or polyurethane condoms when engaging in sex during the study and for at least 28 days after dosing.~Exclusion Criteria:~1. Any condition, including the presence of laboratory abnormalities, or psychiatric illness, that would prevent the subject from signing the Informed Consent form, places the subject at unacceptable risk if he were to participate in the study, or confounds the ability to interpret data from the study.~2. Presence of any surgical or medical conditions possibly affecting drug absorption, distribution, metabolism, and excretion, or plans to have elective or medical procedures during the conduct of the trial.~3. Exposure to an investigational drug (new chemical entity) within 30 days prior to the first dose administration or 5 half-lives of that investigational drug, if known (whichever is longer).~4. Subjects with known serum hepatitis, is a known carrier of hepatitis B surface antigen, hepatitis C antibody, or human immunodeficiency virus antibody.~5. Subjects who have used prescription systemic or topical medications within 30 days of dosing, unless it is being used to treat a stable, chronic medical condition. This includes medication that is an inhibitor or inducer of P-glycoprotein transporter and CYP-3A4/5 used within 14 days of dosing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Sequence 1: Apremilast Fasted / Fed (Type: EXPERIMENTAL): In Period 1 participants will receive a single 30 mg apremilast tablet administered under fasted conditions and in Period 2 participants will receive a single 30 mg apremilast tablet administered after a high fat meal.
- Sequence 2: Apremilast Fed / Fasted (Type: EXPERIMENTAL): In Period 1 participants will receive a single 30 mg apremilast tablet administered after a high fat meal and in Period 2 participants will receive a single 30 mg apremilast tablet administered under fasted conditions.

Based on this trial design, predict the completion outcome and termination type (if applicable).